S-1: Panbela Therapeutics Eyes CBOE Listing with Proposed Public Offering and Reverse Stock Split

Panbela Therapeutics is undertaking a firm commitment public offering of common stock and warrants, alongside a proposed reverse stock split, to meet listing requirements for the US Equity Listings Tier II of the CBOE.

Summary

• Panbela Therapeutics is planning a firm commitment public offering involving shares of common stock, Class G and Class H warrants, and potentially pre-funded warrants.
• The offering aims to raise capital for the continued clinical development of ivospemin and eflornithine, as well as for working capital and general corporate purposes.
• The company has applied to list its common stock on the US Equity Listings Tier II Chicago Board of Options Exchange (CBOE).
• A reverse stock split, with a ratio ranging from 1-for-10 to 1-for-45, is proposed to increase the per share market price to meet CBOE listing requirements.
• The underwriter, Roth Capital Partners, has an option to purchase up to 4,360,465 additional shares and warrants within 45 days.
• The company's common stock became eligible for quotation on the OTCQB market on April 17, 2024, under the symbol PBLA.
• The company intends to file a Form 25 to withdraw its listing from The Nasdaq Stock Market LLC (Nasdaq).

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is actively pursuing a CBOE listing and raising capital, it also faces financial challenges and has been delisted from Nasdaq. The success of the company depends on the outcome of clinical trials and regulatory approvals.

Positives

• The offering will provide capital for the continued clinical development of the company's product candidates.
• The company is actively pursuing a listing on the CBOE, which could increase visibility and liquidity.
• The company has a licensing agreement with the Arizona Board of Regents of the University of Arizona.
• The company has a research agreement with the Johns Hopkins University School of Medicine.

Negatives

• The company has a history of negative operating cash flow.
• The company's auditors have expressed substantial doubt regarding its ability to continue as a going concern.
• The company's common stock was delisted from Nasdaq.
• The company is seeking stockholder approval for a reverse stock split with a ratio between 1-for-10 and 1-for-45 to meet CBOE listing requirements.
• There is no established public trading market for the warrants being offered in this offering.

Risks

• The company's ability to obtain additional capital is uncertain.
• The company faces intense competition in the pharmaceutical and biotechnology industries.
• Clinical trials are expensive and time-consuming, and their outcome is highly uncertain.
• The company relies on third parties for the production of its product candidates.
• The company may be exposed to infringement or misappropriation claims by third parties.
• Failure to obtain or maintain the listing of the company's common stock on a national securities exchange could seriously harm the liquidity of its stock and its ability to raise capital.
• If you purchase shares of common stock in this offering, you will incur immediate and substantial dilution in the book value of the shares of our common stock.

Future Outlook

The company intends to use the net proceeds from this offering for the continued clinical development of its product candidates ivospemin and eflornithine and for working capital, and other general corporate purposes, which may include repayment of debt.

Industry Context

The pharmaceutical and biotechnology industries are highly competitive and characterized by rapid and significant technological change. Panbela faces intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies.

Stakeholder Impact

• Shareholders may experience dilution as a result of the public offering.
• Shareholders may experience an increase in share price if the company is successful in listing on the CBOE.
• The company's employees and customers may benefit from the continued development of its product candidates.
• The company's creditors may benefit from the repayment of debt.

Next Steps

• Obtain stockholder approval for the proposed reverse stock split.
• Secure a listing on the CBOE.
• Continue clinical development of ivospemin and eflornithine.
• Pursue regulatory approvals in the United States, the European Union, and other international markets.

Key Dates

Keywords

Panbela Therapeutics, public offering, reverse stock split, CBOE, ivospemin, eflornithine, warrants, clinical development, OTCQB, Nasdaq, PBLA